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ARTICLE
5-ﬂuorocytosine resistance is associated with
hypermutation and alterations in capsule
biosynthesis in Cryptococcus
R. Blake Billmyre 1,3,4, Shelly Applen Clancey1,4, Lucy X. Li2, Tamara L. Doering2 & Joseph Heitman1*
Patients infected with the fungal pathogen Cryptococcus are most effectively treated with a
combination of 5-ﬂuorocytosine (5FC) and amphotericin B. 5FC acts as a prodrug, which is
converted into toxic 5-ﬂuorouracil (5FU) upon uptake into fungal cells. However, the
pathogen frequently develops resistance through unclear mechanisms. Here we show that
resistance to 5FC in Cryptococcus deuterogattii is acquired more frequently in isolates with
defects in DNA mismatch repair that confer an elevated mutation rate. We use whole
genome sequencing of 16 independent isolates to identify mutations associated with 5FC
resistance in vitro. We ﬁnd mutations in known resistance genes (FUR1 and FCY2) and in a
gene UXS1, previously shown to encode an enzyme that converts UDP-glucuronic acid to
UDP-xylose for capsule biosynthesis, but not known to play a role in 5FC metabolism.
Mutations in UXS1 lead to accumulation of UDP-glucuronic acid and alterations in nucleotide
metabolism, which appear to suppress toxicity of both 5FC and its toxic derivative 5FU.
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One of the key challenges of the 21st century is theemergence and reemergence of pathogens. Opportunisticfungal pathogens comprise an important component of
this problem as they infect the rapidly expanding cohort of
immunocompromised patients1. These pathogens are respon-
sible for millions of infections annually, with substantial mor-
tality. Among the most dangerous are Cryptococcus species that
cause ~220,000 infections a year, with >181,000 attributable
deaths2. Cryptococcosis is particularly prominent in Sub-
Saharan Africa, where the HIV/AIDS epidemic has resulted in
a large population of susceptible individuals. Cryptococcosis is
treated most effectively using a combination of 5-ﬂuorocytosine
(5FC) and amphotericin B3,4. However, in the parts of Africa
where patients are most commonly afﬂicted with cryptococcosis,
the medical infrastructure is insufﬁcient to allow treatment with
the highly toxic amphotericin B component of this dual therapy.
Instead patients are typically treated with ﬂuconazole mono-
therapy, with limited success. Excitingly, recent studies have
shown that 5FC can be effectively paired with ﬂuconazole to
replace amphotericin B for treatment of patients in Africa5.
However, 5FC is not yet approved or available for treatment in
any African countries.
5FC acts as a prodrug, which enters cells via the cytosine
permease Fcy2. 5FC itself is not toxic, but upon uptake into
fungal cells, it is converted into toxic 5-ﬂuorouracil (5FU) by
cytosine deaminase, an enzyme that is not present in human
cells6. In Cryptococcus, and other fungi, cytosine deaminase is
encoded by the FCY1 gene. 5FU is then further processed by the
product of the FUR1 gene, a uracil phosphoribosyltransferase,
and inhibits both DNA and protein synthesis. Resistance is well
understood in other fungal pathogens, like Candida albicans,
where loss of function mutations in FCY1, FCY2, and FUR1 can
mediate resistance to 5FC7. In Candida lusitaniae, mutations in
FUR1 can be readily distinguished from mutations in FCY1 and
FCY2 because only fur1 mutations result in cross-resistance to
5FU8. Likewise, in Candida dubliniensis, natural missense fur1
mutations affect both 5FC and 5FU resistance9. However, little
work has been conducted on 5FC resistance directly in Crypto-
coccus. One of the few early studies suggested that reductions in
FUR1 activity may be linked to resistance to 5FC based on a high
frequency of cross-resistance to 5FU10. However, this study took
place prior to the cloning or sequencing of the FUR1 gene in
Cryptococcus and attribution of resistance to FUR1 was based
only on cross-resistance to 5FU. More recent studies of 5FC
resistant Cryptococcus bacillisporus isolates found no mutations in
FCY1, FUR1, or any of three putative FCY2 paralogs that
explained drug resistance11. However, in Cryptococcus deuter-
ogattii, deletions of FCY2 confer resistance to 5FC12.
Recent work has demonstrated one source of increased rates of
resistance to antifungal drugs in Cryptococcus: defects in the DNA
mismatch repair pathway13,14. Natural isolates with DNA mis-
match repair defects have been identiﬁed in both an outbreak
population of Cryptococcus deuterogattii13,15 and in Cryptococcus
neoformans14,16. Defects in mismatch repair are also common in
other human fungal pathogens, including Candida glabrata17.
Depending on the population studied, multidrug resistance is
sometimes linked to the hypermutator state in C. glabrata18,19. A
recent study of clinical C. glabrata isolates in India found a high
prevalence ofmsh2mutation, but no drug resistance20. This could
suggest that hypermutation is advantageous even prior to drug
exposure, while also providing more rapid development of
resistance when antifungal drugs or agents are encountered.
Alternatively, hypermutation has also been observed in more
ancient lineages of fungi not known to be pathogenic, suggesting
that hypermutation may have general advantages in a broader
range of settings21.
Here we demonstrate that DNA mismatch repair defects also
enable rapid resistance to 5FC in C. deuterogattii (previously
known as C. gattii VGII22–24). We utilize whole genome Illumina
sequencing, in combination with candidate-based Sanger
sequencing, to identify the genetic basis for drug resistance in 16
independent isolates. We attribute resistance to mutations in
FUR1 and unexpectedly, we also identify a pathway of resistance
to 5FC involving mutations in the pathway responsible for pro-
ducing the capsule, a core component of cryptococcal virulence.
Results
Hypermutation mediates resistance to 5FC. In a previous study,
we demonstrated that mismatch repair mutations conferred
increased rates of resistance to the antifungal drugs FK506 and
rapamycin13. Because these hypermutator strains are found
among both environmental and clinical isolates, here we tested if
a hypermutator state could also confer resistance to one of the
front-line drugs used to treat Cryptococcosis: 5-ﬂuorocytosine
(5FC). A semi-quantitative swabbing assay was ﬁrst employed to
demonstrate that deletions of the mismatch repair gene MSH2 in
Cryptococcus deuterogattii confer an elevated rate of resistance to
5FC (Fig. 1a). This result was conﬁrmed using a quantitative
ﬂuctuation assay approach (Fig. 1b). This assay revealed a greater
than 15-fold increase in the generation of resistance to 5FC in
msh2Δ mismatch repair defective mutants. Similarly, a simple
spreading assay using VGIIa-like strains that had previously been
found to harbor an msh2 nonsense allele13 demonstrated a much
higher rate of resistance to both 5FC and 5FU than in the VGIIa
non-hypermutator strains (Supplementary Fig. 1).
In previous studies, mutator alleles in C. deuterogattii were not
found to be generally advantageous in rich media13. However,
under stressful conditions, such as drug challenge with FK506 and
































Fig. 1 5FC resistance is enhanced by defects in mismatch repair. a Swab
assays were conducted using both the wildtype R265 strain and two
independent msh2Δ::NEO mutants to test for the ability to generate
resistance to 5FC. All three strains developed resistance; however, the
mismatch repair mutants generated resistant isolates at a higher frequency.
b A ﬂuctuation assay was conducted to compare 5FC resistance
quantitatively between wildtype R265 and two independent msh2Δ::
NEO mutants. Mutation rate was normalized to the wildtype strain. Red is
used to indicate wildtype strains while green indicates msh2 deletion
strains. Both mutator strains showed a greater than 15-fold increase in the
rate of resistance. Data shown are the mean of 10 replicates and error bars
indicate 95% conﬁdence intervals.
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growth experiment was utilized to test the same concept with 5FC.
Mutator strains became resistant to 5FC at a higher rate and thus
rapidly outcompeted wildtype strains (Fig. 2). However, in the
absence of added stress, the mutator alleles showed no such
advantage. This result suggests that drug challenge during
infection may select for strains with elevated mutation rates that
are able to acquire drug resistance more rapidly.
A subset of 5FC resistance is mediated by FUR1 mutation. In
other fungi, resistance to 5FC is typically mediated by mutations
in one of three genes: FCY1, FCY2, or FUR17,8,10,25. As described
above, mutations in FCY1 and FCY2 are typically distinguishable
from fur1 mutations because mutations in FUR1 confer resistance
not only to 5FC but also to 5FU. In contrast, fcy1 and fcy2
mutations confer resistance to only 5FC. To deﬁne the mechan-
ism underlying 5FC resistance in C. deuterogattii, 29 resistant
colonies were isolated and tested, originating from the wildtype
(R265, 9 colonies) and from two independent msh2Δ mutants
derived in the R265 background (RBB17, 10 colonies and RBB18,
10 colonies). Cultures were started from independent colonies
and a single resistant colony was selected from each culture, so
that only one resistant isolate is derived from any original colony
derived from the frozen stock. All of the 5FC resistant isolates
(Table 1) acquired were cross-resistant to 5FU (29/29) (Fig. 3a),
leading us to hypothesize that resistance to 5FC in C. deuterogattii
was most commonly mediated by mutations in FUR1.
However, when the FUR1 gene was Sanger sequenced in this
set of 5FC/5FU resistant isolates, unexpectedly, only three out of
29 isolates (10.3%) were found to have sustained mutations in
FUR1 (R265-3, R265-4, and R265-6) (Table 1), although PCR
ampliﬁcation of the FUR1 locus failed for another 3 isolates
(R265-2, R265-7, R265-8), suggesting a possible large deletion or
insertion event. Because fur1 mutations were the only known
cause of 5FC/5FU cross-resistance, we performed whole genome
Illumina sequencing on a subset of the remaining isolates
(22 isolates) to identify unknown genes underlying resistance.
We sequenced the whole genomes of 5 additional R265 isolates, 8
additional RBB17 isolates, and 9 additional RBB18 isolates, for a
total of 22 5FC and 5FU resistant isolates.
From the sequenced genomes, reads were aligned to the R265
reference genome and SNPs and indels were identiﬁed. This
analysis revealed that one pair of the presumed independent
isolates were in fact siblings (RBB17-3 and RBB17-4), resulting in
a total of 5 independent R265 genomes, 7 independent RBB17
genomes, and 9 independent RBB18 genomes (21 total indepen-
dent isolates).
Of these 21 independent genome sequences, six contained
unambiguous mutations in FUR1 that were not detected by
Sanger sequencing. The ﬁrst fur1 mutation discovered by whole
genome sequencing was a single base deletion that introduced a
frameshift (R265-1). Two sets of homopolymer shifts were also
identiﬁed in FUR1: a single base deletion in a 6xA homopolymer
run at position 1358 found in three independent isolates (RBB17-
5, RBB18-2, and RBB18-5) and a single base deletion in a 5xT
homopolymer run at position 1027. Finally, a mutation within a
splice acceptor (G to A) was identiﬁed at position 448 (RBB17-8).
For three 5FC resistant R265 strains (R265-2, R265-7, R265-8),
PCR ampliﬁcation of the FUR1 locus failed and subsequent whole
genome sequencing revealed regional deletions consistent with
these failed PCRs. For two strains, break points were clearly
identiﬁable. R265-7 sustained a deletion of bases 189022-203758
(14,736 bp) surrounding FUR1, while R265-8 sustained a deletion
of bases 190136-216860 (26,724 bp), also including FUR1. For
R265-2, one end of the deletion lies within FUR1, eliminating one
of the primer binding sites and consistent with the failed PCR.























YNB YNB + 5FC
All competed against R265
Fig. 2 Exposure to 5FC generates an adaptive advantage for mutator
strains. Competition experiments between a tester strain with a neomycin
resistance marker and a wildtype R265 strain. (Strains used: SEC501,
RBB17, RBB18). Overnight cultures were mixed 1:1 and then used to
inoculate a second overnight culture in liquid YNB with and without 5FC. All
three marked strains showed a slight growth defect in comparison to the
unmarked strain in nonselective media but only the hypermutator strains
demonstrated a dramatic growth advantage when grown in YNB+ 5FC.
Boxplots show minimum, ﬁrst quartile, median, third quartile, and
maximum values. Points represent the results from three individual
replicates and are summarized by the box plot. The R265 NEOR vs wildtype
competition is gray, while the two independent msh2Δ::NEO vs wildtype
competitions are dark and light blue.
Table 1 5FC-resistant isolates whole genome sequenced or




R265-1 Wildtype fur1 1134delT
R265-2 Wildtype ~18.5 kb deletion spanning fur1
R265-3 Wildtype fur1 1003delT, mutation detected
via Sanger
R265-4 Wildtype fur1 1136delT, mutation detected
via Sanger
R265-5 Wildtype uxs1 1520delT
R265-6 Wildtype fur1 1440delA, mutation detected
via Sanger
R265-7 Wildtype ~14.7 kb deletion spanning fur1





RBB17-5 msh2Δ::NEO fur1 1358delA in 6 base homopolymer
RBB17-6 msh2Δ::NEO
RBB17-7 msh2Δ::NEO
RBB17-8 msh2Δ::NEO fur1 G448A (splice acceptor)
RBB18-1 msh2Δ::NEO
RBB18-2 msh2Δ::NEO fur1 1358delA in 6 base homopolymer
RBB18-3 msh2Δ::NEO
RBB18-4 msh2Δ::NEO fcy2 Trp167Stop
uxs1 Asp306Gly
RBB18-5 msh2Δ::NEO fur1 1358delA in 6 base homopolymer
RBB18-6 msh2Δ::NEO fur1 1027delT in 5 base homopolymer
RBB18-7 msh2Δ::NEO
RBB18-8 msh2Δ::NEO uxs1 1182insC in 7 base homopolymer
RBB18-9 msh2Δ::NEO uxs1 Tyr217Cys
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gap of the annotated V2 R265 reference genome. To identify the
precise location of this second breakpoint, reads from R265-2
were mapped to a recent Nanopore and Illumina hybrid assembly
of the R265 strain26. Interestingly, the second breakpoint was
found within a gene encoding a weak paralog of FUR1 (5 × 10−10
protein BLAST e-value). This paralog (CNBG_4055) is also
present in C. neoformans (CNAG_2344), suggesting that if it
arose via duplication, it was before the last common ancestor to
both species. Given that deletion of FUR1 confers resistance to
5FC and 5FU, it is unlikely that this paralog performs the same
function as Fur1 (Fig. 3a). Despite the protein similarity, no
obvious nucleotide homology was found that may have mediated
this large deletion conferring 5FC resistance. In fact, the FUR1
paralog is inverted relative to FUR1, reducing the likelihood that
remnant homology may have generated a region susceptible to
frequent homology-mediated deletion of FUR1 that would yield
the type of regional deletion observed here.
A Trp167STOP mutation in FCY2 (CNBG_3227) was also
detected in the sequenced set (RBB18-4). Mutations in FCY2 were
unexpected because in other fungi they do not confer resistance
to 5FU and because there are 2 additional paralogs with
substantial similarity to FCY2 present in the Cryptococcus
genome. Because this fcy2 strain also contains a second mutation
in a gene that plays a role in 5FC and 5FU resistance (discussed
below), the fcy2 mutation may be unrelated to drug resistance or
may enhance resistance in the presence of the second mutation.
We attempted to test the ortholog of FCY2 from Cryptococcus
neoformans using a deletion collection strain but found that the
mutant in the collection retained a functional copy of the FCY2
gene. However, fcy2 deletion has recently been reported to confer
resistance to 5FC in C. deuterogattii12.
In total, out of 29 original 5FC resistant strains (Table 1),
twelve independent fur1 mutations were identiﬁed using Sanger
and Illumina sequencing. One independent fcy2 mutation was
identiﬁed by Illumina sequencing. We did not identify any fcy1
mutations, although fcy1 mutations confer resistance to 5FC in C.
neoformans (Supplementary Fig. 2).
Mutations in UXS1 also confer resistance to 5FC. In total,
11 sequenced genomes representing 10 independent isolates
remained with no mutations in any genes previously described to
have a role in 5FC or 5FU resistance. These genomes were
examined to identify candidate mutations. To distinguish causal
variants from background mutations, candidate genes were
required to be mutated in at least two different independent
isolates. Variant impact was also scored using SNPeff27 and
mutations were not considered if predicted to have low impact
(i.e., synonymous, intronic, or non-coding variants). Mutations of
moderate or higher impact were identiﬁed at a total of 128 sites
(Supplementary Data 1). To further prioritize, we speciﬁcally
focused on mutations that were present in isolates from more
than one of the parental backgrounds. We identiﬁed UXS1, which
sustained four distinct mutations in four isolates from two par-
ental backgrounds (Fig. 3b).
UXS1 encodes the enzyme that converts UDP-glucuronic acid
to UDP-xylose28. This pathway is critical for the formation of the
capsule, a core virulence trait of Cryptococcus, and for synthesis of
other glycoconjugates. There is no UXS1 ortholog in either
Saccharomyces cerevisiae or Candida albicans, where many of the
resistance mechanisms for 5FC were elucidated. The mutations in
UXS1 included a single base deletion in a 3xT homopolymer
(R265-5), a single base insertion in a 7xC homopolymer (RBB18-
8), and a missense mutation (Tyr217Cys, RBB18-9) (Fig. 3b,
Table 1). Finally, a uxs1 mutation (Asp306Gly) was identiﬁed in
the isolate previously identiﬁed to have an fcy2 mutation (RBB18-
4). In sum, 9 sequenced genomes representing 8 independent
isolates remained for which we were unable to identify a mutation
that conferred resistance to 5FC and 5FU, all derived from msh2
mutant isolates.
To conﬁrm the role of uxs1 mutation in resistance to 5FC and
5FU, a uxs1 deletion available from a C. neoformans deletion
collection was employed (Fig. 4a). This uxs1Δ strain was
completely resistant to both drugs, suggesting that all four alleles
isolated were likely loss of function mutations because they
shared a drug resistance phenotype with the null mutant. We
tested the MIC of 5FC for uxs1 and fur1 mutants in both YPD
and YNB using a broth microdilution assay. Both uxs1 and fur1
mutants were resistant to 5FC above the limits of our assays
(MIC > 400 µg/mL in YPD and > 4 µg/mL in YNB) while the
wildtype parent strains were sensitive at 200 µg/mL in YPD and
0.5 µg/mL in YNB (Table 2).
Accumulation of UDP-glucuronic acid mediates 5FC resis-
tance. We next sought to genetically deﬁne the mechanism by
which drug resistance may be mediated by loss of uxs1 function.
Multiple models were considered to explain why 5FC/5FU toxi-
city would require Uxs1. The ﬁrst was that Uxs1 directly converts
5FU into a toxic product. If so, Uxs1 and Fur1 would function in
the same pathway, as either mutant independently confers drug
resistance. This hypothesis was tested using an overexpression
allele of UXS1 that is driven by the actin promoter29. If this
hypothesis were correct, we would expect to observe additional
sensitivity conferred by the overexpression allele compared to
wildtype. By reducing the amount of 5FU used to only 1 µg/mL,
wildtype strains were only partially inhibited. However, intro-
duction of an overexpression allele of UXS1 did not increase
sensitivity (Fig. 4b). This suggests that Uxs1 does not act by
converting 5FU or a 5FU derivative into a toxic product.
We next tested whether 5FC resistance in uxs1 mutants may
occur through an indirect effect of the role of Uxs1 in synthesis of
UDP-xylose. UDP-xylose is the donor molecule for xylose
addition to glycans, a process that primarily occurs in the
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Fig. 3 5FC resistant mutants are cross-resistant to 5FU. a Isolates that
were selected based on growth on 5FC media were patched to YNB, YNB
plus 5FC, and YNB plus 5FU. Each plate has parental and fur1 mutant
controls in the top row. Hypermutator controls have occasional resistant
colonies that emerged in the growth patch. Sanger and Illumina sequencing
revealed that 12 of 29 isolates had sustained mutations in FUR1. b Schematic
showing the predicted domains encoded by the UXS1 gene, as well as the
location and number of mutations identiﬁed. Frame-shift alleles are shown in
red and missense are shown in blue.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13890-z
4 NATURE COMMUNICATIONS |          (2020) 11:127 | https://doi.org/10.1038/s41467-019-13890-z | www.nature.com/naturecommunications
glycoconjugate is required to mediate 5FC toxicity, mutation of
UXS1 would indirectly confer drug resistance. To test this,
deletion mutants lacking transporters that move UDP-xylose into
the secretory compartment (uxt1, uxt2, and a uxt1 uxt2 double
mutant30) or that lack Golgi xylosyl-transferases that act in
protein, glycolipid, and polysaccharide synthesis (cxt131, cxt2, and
a cxt1 cxt2 double mutant) were analyzed. None of these mutants
demonstrated any change in sensitivity to 5FC or 5FU (Fig. 4c).
However, these data did not rule out a requirement for a
(previously undescribed) cytoplasmic xylosyl protein modiﬁca-
tion. To test this hypothesis, a mutant that cannot generate UDP-
glucuronic acid, the immediate precursor for UDP-xylose
synthesis was used. This mutant (ugd1) is somewhat growth
impaired relative to wildtype and cannot grow on YNB media.
However, it does grow, albeit poorly, on rich YPD media, where it
clearly exhibited sensitivity to 5FC. This result demonstrated that
xylose modiﬁcation, in any cellular compartment, is not required
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Fig. 4 uxs1 mutants mediate 5FC resistance through a xylosylation-independent mechanism. a KN99 deletion strains from the C. neoformans deletion
collection show that deletion of UXS1 confers resistance to 5FC and 5FU. The RBB18-2 strain carrying a fur1 mutation is resistant to 5FC and 5FU although
more weakly to 5FU. The R265-3 strain carrying a fur1mutation is completely resistant to both drugs. b Spot dilution assay on YNB, YNB plus 5FC, and YNB
plus 5FU demonstrating overexpression of UXS1 driven by the actin promoter does not confer increased sensitivity to 5FC or 5FU. c Spot dilution assays on
YNB, YNB plus 5FC, and YNB plus 5FU demonstrating that mutants deﬁcient in UDP-xylose transport (uxt1Δ, uxt2Δ, uxt1Δ uxt2Δ) and xylose transferase
mutants (cxt1Δ, cxt2Δ, cxt1Δ cxt2Δ) show no change in 5FC and 5FU sensitivity. d Spot dilution assay on YPD, YPD plus 5FC, and YPD plus 5FU showing
that ugd1mutants are viable on rich YPD media but retain sensitivity to 5FC and 5FU. In addition, ugd1 uxs1 double mutants retain sensitivity to 5FC and 5FU
like a ugd1 single mutant rather than gain resistance like the uxs1 single mutant.
Table 2 MIC values for deletion mutants of genes identiﬁed
in this study.
Genetic Background 5FC in YPD 5FC in YNB
Wildtype 200 µg/mL 0.5 µg/mL
fur1 > 400 µg/mL > 4 µg/mL
uxs1 > 400 µg/mL > 4 µg/mL
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The previous models ruled out the lack of UDP-xylose for
synthetic processes as an explanation for 5FC resistance. Another
result of the loss of UXS1 function is the accumulation of UDP-
glucuronic acid, the immediate precursor in the production of
UDP-xylose. Past studies have shown that UDP-glucuronic acid
accumulates to extremely high levels in uxs1 mutant cells, while it
is undetectable in ugd1 mutants32. To test whether this mediates
resistance, we generated a uxs1 ugd1 double mutant, which
should produce neither UDP-glucuronic acid nor UDP-xylose32.
While the uxs1 ugd1 mutant was growth impaired, like the ugd1
single mutant, it was clearly sensitive to 5FC (Fig. 4d). That uxs1
mutants are 5FC resistant, whereas uxs1 ugd1 double mutants are
restored to 5FC sensitivity suggests that accumulation of UDP-
glucuronic acid in uxs1 mutants mediates resistance to 5FC and
5FU (Fig. 5).
Discussion
Treating fungal diseases is complicated both by the limited
number of drugs that effectively treat infection without harming
the patient and by the rapid rate at which fungi develop resistance
to the few drugs that are effective. 5FC is a particularly emble-
matic example of this issue, as it is highly efﬁcacious with limited
toxicity. Human cells lack the ability to convert 5FC to 5FU and
toxicity is conferred only by the conversion of 5FC to the che-
motherapeutic 5FU by a patient’s microbiota33. However, 5FC is
ineffective when used for solo treatment because fungal resistance
rapidly emerges. Here, we demonstrate that DNA mismatch
repair mutants exhibit accelerated acquisition of resistance to
5FC. Evolutionary theory predicts that hypermutators should be
rare in eukaryotic microbes because sex unlinks mutator alleles
from the mutations they generate, eliminating the advantage of an
elevated mutation rate and leaving only the general decrease in
ﬁtness from introduced mutations34. This result lends further
support to the recent appreciation that mismatch repair mutants
may be common in pathogenic fungi in part because treatment
with antifungal drugs increases selection for mutations that
generate resistance13,14,16,17.
We explored the underlying genetic and genomic basis of 5FC
resistance. The resistant mutants in C. deuterogattii selected here
were cross-resistant to 5FU. Sanger and whole genome Illumina
sequencing identiﬁed a presumptive genetic basis for drug resis-
tance in 16 independent isolates. Analysis of resistance loci from
whole genome data was relatively facile in wildtype strains (5/
5 strains assigned a causative mutation), where an average of 1.2
coding mutations (range 0–3) were identiﬁed by whole genome
sequencing, including the putative resistance mutation, relative to
the reference. However, this analysis was substantially more dif-
ﬁcult in mutator strains (8/17) where an average of 11.47 coding
mutations were found per strain (range 2–25), with numerous
additional noncoding or synonymous mutations. For the pur-
poses of identifying the genetic basis of a trait that occurs at a
high rate in wildtype, future studies would be advised to avoid
mutations that increase mutation rate, as they contribute to
background noise.
We identiﬁed multiple mutations in the FUR1 locus (12 of the
16 identiﬁed causative mutations). fur1 mutations occurred
through multiple mechanisms, including regional deletions,
homopolymer tract length changes that introduced frameshift
mutations, and a splice site acceptor point mutation. Surprisingly,
we did not identify mutations in FCY1 or mutations in FCY2 that
were unaccompanied by a second resistance mutation. Although
we selected with only 5FC, all drug resistant isolates were cross-
resistant to 5FU as well. One possible explanation is that selection
with 100 µg/mL of 5FC may be above the MIC for fcy1 or fcy2
mutants in C. deuterogattii, although fcy1 mutants in C. neofor-
mans are resistant to 100 µg/mL of 5FC (Supplementary Fig. 2).
Further experiments will be necessary to test this hypothesis,
which could provide guidance into treatment levels for 5FC.
Further experiments based on this hypothesis could provide
insight into the function of the other FCY2 paralogs, perhaps as
lower afﬁnity transporters of 5FC that confer toxicity at higher
concentrations of 5FC.
Mutations in UXS1 are particularly interesting as a mechanism
of resistance in Cryptococcus because Uxs1 catalyzes the produc-
tion of UDP-xylose, the donor molecule for essential components
of Cryptococcal capsule polysaccharides. Strains lacking UXS1 are
hypocapsular with altered capsule structure32. In addition, uxs1
mutants are avirulent in a murine tail-vein injection disseminated
infection model35. This suggests that uxs1 mutants might be
unlikely to emerge during exposure to 5FC in vivo, even though
they represent a substantial proportion of the resistant isolates
observed in this study. Likewise, regional deletions including
FUR1 affected multiple neighboring genes as well, including the
direct neighboring gene GIS2. Gis2 has previously been described
to play a role in stress tolerance, including ﬂuconazole and oxi-
dative stress tolerance36. Like uxs1 mutants, these regional dele-
tion mutants may be less likely to emerge in vivo. It is important





































Fig. 5 Model of inhibition of 5FC/5FU toxicity by uxs1 mutation. Potential mechanisms by which uxs1 mutations may confer resistance to both 5FC and
5FU. Mutation of uxs1 causes an accumulation of UDP-glucuronic acid, the product of Ugd1, which either impairs production of toxic ﬂuoridated molecules
or rescues inhibition of the targets of those ﬂuoridated molecules, such as thymidylate synthase. Protein names are in red for those where mutations were
found in this study.
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with clinical treatment failure and does not prevent synergy of
combination treatment with Amphotericin B and ﬂucytosine37.
Continued selection by 5FC treatment of a deleterious resistance
allele like a uxs1 mutation or a collateral gis2 deletion might
explain the maintenance of synergy. Future studies examining the
mechanisms of resistance during treatment with 5FC in vivo will
provide further insights into the possible contribution of each of
these mechanisms to resistance in patients.
This study also illustrates the importance of examining drug
resistance in the context of the pathogen being treated. Previous
work in C. albicans and S. cerevisiae suggested that resistance
would occur through mutations in FUR1, but both species are
evolutionarily distant from Cryptococcus and lack a UXS1
ortholog. While these previous studies provided substantial
insight into 5FC toxicity, studies in the pathogen of interest are
essential. Surprisingly, one strain (RBB18-4) that was cross
resistant to 5FU had a mutation in the FCY2 gene (CNBG_3227),
which in other species confers resistance to 5FC but not 5FU.
Mutation of FCY2 is known to result in resistance to 5FC in C.
deuterogattii, but cross-resistance to 5FU has not been tested12.
Unexpected cross-resistance between 5FC and ﬂuconazole has
been previously observed in fcy2 mutants of Candida lusitaniae
but is proposed to occur through competitive inhibition of ﬂu-
conazole uptake by 5FC that can no longer enter through Fcy2-
mediated transport8,38,39. C. lusitaniae fcy2 mutants are not
resistant to ﬂuconazole without the addition of 5FC. In addition,
multiple resistant strains were not assigned a presumptive cau-
sative mutation here and lacked mutations in any genes known to
cause 5FC resistance from this or previous work (FUR1, FCY1,
FCY2, and UXS1). Presumably unknown mechanisms are
responsible for resistance to 5FC and 5FU in these strains as well,
either in pathways unique to Cryptococcus or potentially more
broadly conserved.
In addition, UXS1 mutations provide unexpected insight into
interaction between nucleotide synthesis and generation of pre-
cursors for xylosylation. Surprisingly, accumulation of UDP-
glucuronic acid appears to either inhibit the pyrimidine salvage
pathway or activate thymidylate synthase (Fig. 5). This suggests
that UDP-glucuronic acid may have a role as a source of UDP for
the cell, while UDP-xylose does not. While UXS1 orthologs are not
found in C. albicans or S. cerevisiae, which lack xylose modiﬁca-
tions, there is a UXS1 ortholog in humans. 5FU is commonly used
as a chemotherapeutic drug40, and resistance to 5FU is frequently
associated with mutations in thymidylate synthase41. Data here
suggest that uxs1 mutations may be acting in a similar fashion to
either de-repress thymidylate synthase or inhibit Fur1 (Fig. 5).
Further exploration of the role of Uxs1 orthologs in humans
during 5FU chemotherapy may be of interest.
Methods
Strains and media. The strains and plasmids used in this study are listed in
Table S1. The strains were maintained in 25% glycerol stocks at −80 °C and grown
on rich YPD media at 30 °C (Yeast extract Peptone Dextrose). Strains with
selectable markers were grown on YPD containing 100 µg/mL nourseothricin
(NAT) and/or 200 µg/mL G418 (NEO).
Genome sequencing. DNA was isolated for sequencing by expanding individual
colonies to 50mL liquid cultures in YPD at 30 °C. Cultures were then frozen and
lyophilized until dry. DNA was extracted using a standard CTAB extraction pro-
tocol, as previously described42. Illumina paired-end libraries were prepared and
sequenced by the University of North Carolina Next Generation Sequencing Facility
using the Kapa Library prep kit and the Hiseq platform. Additional sequencing was
performed by the Duke University Sequencing Core using the Kapa Hyper prep kit
and performed using a NovaSeq platform. Raw reads are available through the
Sequence Read Archive under project accession number PRJNA525019.
Genome assembly and variant calling. Reads were aligned to the V2 R265
reference genome43 using BWA-MEM44. Alignments were further processed with
SAMtools45, the Genome Analysis Toolkit (GATK)46, and Picard. SNP and indel
calling was performed using the Uniﬁed Genotyper Component of the GATK with
default settings aside from ploidy= 1. VCFtools47 was utilized for processing of the
resulting calls to remove sites common to all strains (errors in the reference
assembly) and variants were annotated using SnpEff27. All remaining variant calls
were visually examined using the Integrated Genome Viewer (IGV) to remove calls
resulting from poor read mapping48. FungiDB was also used to determine putative
function and orthology of genes containing called variants in the dataset49.
Strain construction. A ugd1Δ mutant was constructed in the KN99a background
as follows. Primers pairs JOHE45233/JOHE45085, JOHE45086/JOHE45087, and
JOHE45088/JOHE45234 were used to amplify 1 kb upstream of UGD1, the neo-
mycin resistant marker, and 1 kb downstream of the UGD1 gene, respectively
(primer sequences available in Supplementary Table 2). To generate the deletion
allele for C. neoformans transformation, all three fragments were cloned into
plasmid pRS426 by transforming S. cerevisiae strain FY83450. Recombinant S.
cerevisiae transformants were selected on SD-uracil media and veriﬁed by spanning
PCR with primer pair JOHE45233/JOHE45234. The resulting PCR product was
introduced into C. neoformans laboratory strain KN99a by biolistic transformation
and transformants were selected on YPD containing neomycin. Putative ugd1Δ
deletion mutants were conﬁrmed by PCR.
uxs1Δ single mutants and ugd1Δ uxs1Δ double mutants were generated via a
genetic cross51. First, the KN99α uxs1Δ mutant from the Hiten Madhani deletion
collection was mated with the wild-type KN99a laboratory strain. Through
microdissection, spores were isolated, germinated, and genotyped via PCR for the
gene deletion and the mating type locus to isolate a MATa uxs1Δ mutant in the
KN99a background. Second, the KN99a uxs1Δ mutant was mated with wild-type
H99. Spores were dissected and genotyped via PCR for the gene deletion and the
mating type locus to isolate H99 uxs1Δ single mutants. Finally, the H99 uxs1Δ
single mutant was crossed with KN99a ugd1Δ to generate ugd1Δ uxs1Δ double
mutants, and the H99 ugd1Δ single mutant.
Spot dilution assays. Single colonies were inoculated into 5 mL of liquid YPD and
grown overnight at 30°C. Cell density was determined using a hemocytometer and
the cultures were diluted accordingly such that 100,000 cells were aliquoted on to
the most concentrated spot and subsequent spots consisted of 10-fold dilutions per
spot. Each strain was spotted onto YPD or YNB alone and onto media also con-
taining 5FC or 5FU at the indicated concentration. Plates were incubated at 30°C
until photographed.
Swab assays. To isolate independent drug resistant strains, the original parent
strains were subcultured from a frozen glycerol stock. Single colonies were used to
inoculate liquid YPD cultures without selection. Those liquid cultures were grown
with shaking until saturation. They were then spread onto drug plates (100 µg/mL
5FC on YNB) using sterile cotton swabs to select for resistant colonies. A single
drug resistant colony was taken from any given liquid culture to ensure inde-
pendence. This assay is only semi-quantitative, as the inoculum is not strictly
controlled between independent cultures when swabbing.
MIC testing. 5-ﬂucytosine was dissolved in water and added to liquid YPD media
in a 96-well plate at 400 µg/mL. 2-fold serial dilutions were performed until a
concentration of 1.56 µg/mL was achieved. For YNB, 5-ﬂucytosine was dissolved in
water and added to liquid YNB media in a 96-well plate at 4 µg/mL. Two-fold serial
dilutions were performed until a concentration of 0.016 µg/mL was achieved. Cell
density of overnight cultures (liquid YPD, 30°C) was determined using a hemo-
cytometer and cultures were adjusted to 105 cells/mL. 100 µl of cell suspension was
added to each well (10,000 cells per well). The 96-well plate was incubated at 30°C
and OD600 readings were taken daily using a Sunrise Tecan instrument and
Magellan software.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Raw reads are available through the Sequence Read Archive under project accession
number PRJNA525019. Strains generated in this study are available upon request.
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